Don't pay just to have an ISA. Find out more
(TSTL.L) Tristel PLC Buy/Sell
Add to portfolio Set Alert Level 2 Desktop Trader
Summary
|
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||
| Date/Time | Headline | Source |
|---|---|---|
| 19-03-10 | RNS |
|
|
RNS Number : 8357I Tristel PLC 19 March 2010 TRISTEL plc Director/PDMR Shareholding Tristel plc ("Tristel" or the "Company"), the infection and contamination control business, has been informed of the following transaction by one of its directors: Paul Swinney, Chief Executive Officer, sold 100,000 Ordinary Shares of 1p each ("Ordinary Shares") in the Company at 56.5 per share on 18 March 2010. Following this transaction, Mr Swinney is beneficially interested in 1,359,742 Ordinary Shares, representing 4.10% of the Company's issued share capital. For further information, please contact:
Tristel PLC
FinnCap Geoff Nash/Rhydian Bankes (Corporate Finance) Tel: 020 7600 1658 Simon Starr (Corporate Broking) This information is provided by RNS The company news service from the London Stock Exchange END
RDSMMGMFZRDGGZZ More |
||
| 08-03-10 | RNS |
|
|
RNS Number : 2007I Tristel PLC 08 March 2010 TRISTEL plc
UNAUDITED INTERIM RESULTS Tristel plc ("Tristel" or the "Group"), the infection and contamination control business, announces its interim results for the 26 week period ended 31 December 2009. Results highlights · Revenue up 28.0% to £4.027m (2008: £3.146m) · Gross profit up 24.1% to £2.540m (2008: £2.047m)
· Pre-tax profit up 39.9% to £0.656m (2008: £0.469m)
· Net assets of £7.867m (2008: £4.354m) · Strong operational cashflow: net cash £0.843m at 31 December 2009 (2008: £0.011m overdraft) Operational highlights · Successful integration of the manufacture of the Medichem product portfolio, boosting Group turnover and increasing utilisation of our manufacturing plant · Increasing take up of Tristel surfaces range by UK hospitals aided by their inclusion in the National Patient Safety Agency's "Revised Healthcare Cleaning Manual" · Overseas sales increased by 20% on previous period. Significant expansion opportunities overseas. · Fund raising to satisfy institutional demand completed on 26 November 2009, raising £2m · Funds deployed to accelerate registration programmes for Tristel products in key overseas markets
Commenting on current trading, Paul Swinney, Chief Executive of Tristel, said: "The first half has seen yet another strong performance from the Group. Integrating the manufacture of the Medichem portfolio of disinfectants, which we acquired on 3 July, has been challenging, but successful and has made a significant contribution to top line growth. Our Tristel products have continued to win new hospital customers in the United Kingdom and overseas, with overseas sales increasing by 20% on the comparable period last year. "Reflecting our continuing progress we are pleased to announce the payment of an interim dividend of 0.425p, a 5% increase on last year."
For further information, please contact:
Tristel PLC
FinnCap Geoff Nash/Rhydian Bankes (Corporate Finance) Tel: 020 7600 1658 Simon Starr (Corporate Broking) Chairman's Statement The first half has seen a very strong performance from the Group. Manufacture of the Medichem portfolio of disinfectant products, which was acquired on 3 July 2009, has been successfully integrated into our Newmarket facility. The Medichem product range contributed £0.594m to the increase in the Group's first half turnover. By December 2009 we had taken over the blending and packing of approximately 65% of the portfolio by value and the remainder will be manufactured in house during the second half. Because of the phased transition of manufacture from the previous supplier, some of the gross margin from this activity has yet to be captured and we anticipate an improvement in margins in the second half. Turnover in the Tristel portfolio of chlorine dioxide based disinfectants increased by 9.1%. We continue to make excellent progress in securing new hospital users of our surface disinfection products. In almost all cases we are replacing chlorine (hypochlorite) based products, chlorine being the chemistry most widely used by hospitals for general surfaces. Take up of our products has been greatly aided by our inclusion in the National Patient Safety Agency's "Revised Healthcare Cleaning Manual" published in June 2009. The Manual acknowledges Tristel as one of the new technologies benefitting hospitals for terminal cleans and during infection outbreaks. Turnover generated by overseas distributors and subsidiaries increased to £0.184m in the first half, a 20% increase on the comparable period last year. We aim to continue this growth and are pressing ahead with the registration of Tristel products in many important markets, including Russia and China. We deployed part of the proceeds of the £2m share issue concluded in November 2009 to accelerate this process. Overheads have been successfully controlled during the period with a 19.1% increase in overheads trailing revenue growth. Pre-tax profits increased by 39.9% and Basic EPS by 29.3% Dividend We are declaring an interim dividend of 0.425p, an increase of 5%. The dividend will be paid on 31 March 2010 to shareholders on the register at the close of business on 19 March 2010. Current trading Infection control continues to be a key issue within the National Health Service. It is equally a top priority in all the overseas markets in which we operate. Our Tristel products are innovative, have a well proven safety record and are amongst the highest performing biocides. As a consequence, we believe that our core activity of hospital infection control will be resilient to the financial constraints being imposed on hospitals. Through acquisition and organic growth the Group has become larger, more diversified in the areas within healthcare in which our technology and products are used, has gained exposure to animal healthcare through the Medichem portfolio and is more effectively using its manufacturing capability. We are well placed to continue our unbroken record of revenue and profits growth and look forward to a successful second half of the year. Francisco A. Soler
CONDENSED CONSOLIDATED INCOME STATEMENT
RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2009
share based payments (IFRS2)
depreciation and amortisation
other
Attributable to:
472 332 919
Profit per share from
continuing operations
holders of the parent
All amounts relate to continuing operations.
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE SIX MONTHS ENDED 31 DECEMBER 2009
Other comprehensive income
translating foreign operations
of tax
the period
Attributable to:
462 332 919
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE SIX MONTHS ENDED 31 DECEMBER 2009
December 2008
June 2009
December 2009
translating foreign operations
CONDENSED CONSOLIDATED BALANCE SHEET
AS AT 31 DECEMBER 2009
Non-current assets
Current assets
Capital and reserves attributable to the company's equity
holders
holders of parent
Current liabilities
borrowings
Non-current liabilities
borrowings
CONDENSED CONSOLIDATED CASH FLOW STATEMENT
FOR THE SIX MONTHS ENDED 31 DECEMBER 2009
Cash flows from operating
activities
activities
Cash flows from Investing
activities
and equipment
plant and equipment
activities
Cash flows from Financing
activities
activities
and cash equivalents
the beginning of the period
the end of the period
NOTES TO THE ACCOUNTS
FOR THE SIX MONTHS ENDED 31 DECEMBER 2009 1. PRINCIPal ACCOUNTING POLICIES Basis of Preparation For the year ending 30 June 2009, the Group prepared consolidated financial statements under International Financial Reporting Standards ('IFRS') as adopted by the European Commission. These will be those International Accounting Standards, International Financial Reporting Standards and related interpretations (SIC-IFRIC interpretations), subsequent amendments to those standards and related interpretations, future standards and related interpretations issued or adopted by the IASB that have been endorsed by the European Commission. This process is ongoing and the Commission has yet to endorse certain standards issued by the IASB. These condensed consolidated interim financial statements have been prepared under the historical cost convention. They are based on the recognition and measurement principles of IFRS in issue as adopted by the European Union (EU) and which are, or are expected to be, effective at 30 June 2010. They do not include all of the information required for full annual financial statements, and should be read in conjunction with the consolidated financial statements of the Group for the year ended 30 June 2009. These condensed consolidated interim financial statements (the interim financial statements) have been prepared in accordance with the accounting policies adopted in the last annual financial statements for the year to 30 June 2009. The accounting policies have been applied consistently throughout the Group for the purposes of preparation of these condensed consolidated interim financial statements. Accounting Policies The interim report is unaudited and has been prepared on the basis of IFRS accounting policies. The accounting policies adopted in the preparation of this unaudited interim financial report are the same as the most recent annual financial statements being those for the year ended 30 June 2009 other than in respect of a new accounting policy for deferred consideration. The group adopted IFRS 8, Operating Segments, early by including them in the financial statements for the year ended 30 June 2009. Segments The Group adopted IFRS 8 with effect from its 30 June 2009 and reports its entire activities as one business. Accordingly, the Directors consider currently there to be only one reportable segment, being the development, manufacture and supply of products which utilise the group's chlorine dioxide technologies. Deferred Contingent Consideration on Purchase of Intangibles Where a liability arising from an intangible asset acquisition is contingent on future events, if it is considered that further consideration is probable and its fair value can be measured reliably, the probable contingent payment is included in the cost of the acquisition of the Intangible at the acquisition date, to be flexed, where appropriate against the final deferred payment. 2. Publication of non-statutory accounts The financial information for the six months ended 31 December 2009 and 31 December 2008 has not been audited and does not constitute full financial statements within the meaning of Section 434 of the Companies Act 2006. The financial information relating to the year ended 30 June 2009 does not constitute full financial statements within the meaning of Section 434 of the Companies Act 2006. This information is based on the Group's statutory accounts for that period. The statutory accounts were prepared in accordance with International Financial Reporting Standards ("IFRS") and received an unqualified audit report and did not contain statements under Section 498(2) or (3) of the Companies Act 2006. These financial statements have been filed with the Registrar of Companies.
The calculation of earnings per share is based on the following profits and number of shares:
Reconciliation to reported earnings (net of tax at 28%):
intangibles
2)
4. RECONCILIATION OF operating PROFIT to net cash outflow from operating activities
Adjustments for:
intangibles
(IFRS2)
property plant and equipment
rates
movement in working capital
and other receivables
and other payables
activities
On 3rd July 2009 the Group acquired the intellectual property and manufacturing rights to a portfolio of infection control products manufactured by Medichem International (Manufacturing) Limited, a private company incorporated in England and Wales ("Medichem"). The total cost of the intangibles included in these Interim Financial Statements amounts to £2.48M of which deferred contingent consideration amounts to not less than £1.15 million but subject to a maximum of £1.4 million, payable over 5 years, calculated as a percentage of sales of Medichem products. Monies totalling £1.08 million were paid during the period.
Management have included the maximum amount payable of £2.48M in these Interim Financial Statements, based on current performance and expectation and consider this amount to be the fair value of the purchase.
This information is provided by RNS The company news service from the London Stock Exchange END
IR EAPDSEFNEEFF More |
||
| 25-02-10 | RNS |
|
|
RNS Number : 6357H Tristel PLC 25 February 2010 Tristel PLC ("Tristel") Change of Adviser Tristel is pleased to announce the appointment of FinnCap as Nominated Adviser and Broker with immediate effect. For further information:
Tristel PLC
FinnCap Geoff Nash (Corporate Finance) Tel: 020 7600 1658 Simon Starr (Corporate Broking) This information is provided by RNS The company news service from the London Stock Exchange END
APPPGUAAPUPUGQC More |
||
| Date/Time | Subject | Author | ||
|---|---|---|---|---|
| 08-03-10 |
1
|
|||
|
| ||||
|
| ||||
|
Last year H2 Pre-tax £816,000
Last year H2 EPS 2.04p Today's H1 Results do not look very good against last year's H2 Results. ws |
||||
| 05-03-10 | ||||
|
| ||||
|
| ||||
|
good move pj soon be back to 60s+ at this rate
|
||||
| 26-02-10 | ||||
|
| ||||
|
| ||||
| 25-02-10 |
BUY
bargain
|
|||
|
| ||||
|
| ||||
|
Im fully comitted to this stock.
At this price a BARGAIN |
||||
They have not been approved or issued by Interactive Investor Trading Limited.
Discussion Board Terms & Conditions FSA Market Abuse Fact Sheet
More...